Chelidonium majus Induces Apoptosis of Human Ovarian Cancer Cells via ATF3- Mediated Regulation of Foxo3a by Tip60

키워드

참고문헌 (61)

1. Zhou Q, "Microwave-assisted extraction in combination with capillary electrophoresis for rapid determination of isoquinoline alkaloids in Chelidonium majus L", Talanta, 99, pp.932~938 (2012)
2. El-Readi MZ, "Modulation of multidrug resistance in cancer cells by chelidonine and Chelidonium majus alkaloids", Phytomedicine, 20, pp.282~294 (2013)
3. Van Wyk B-E, "Medicinal plants of the world : an illustrated scientific guide to important medicinal plants and their uses", pp.102~ (2004), Timber Press
4. Kohn L, "Health and long life the Chinese way", pp.131~ (2005), Three Pines Press
5. Deljanin M, "Chelidonium majus crude extract inhibits migration and induces cell cycle arrest and apoptosis in tumor cell lines", J. Ethnopharmacol, 190, pp.362~371 (2016)
6. Herrmann R, "Effect of chelidonine on growth, invasion, angiogenesis and gene expression in head and neck cancer cell lines", Oncol. Lett, 16, pp.3108~3116 (2018)
7. Capistrano IR, "In vitro and in vivo investigations on the antitumour activity of Chelidonium majus", Phytomedicine, 22, pp.1279~1287 (2015)
8. Xie YJ, "Chelidonine selectively inhibits the growth of gefitinib-resistant non-small cell lung cancer cells through the EGFR-AMPK pathway", Pharmacol. Res, 159, pp.104934~ (2020)
9. Radim Havelek, "Comparative cytotoxicity of chelidonine and homochelidonine, the dimethoxy analogues isolated from Chelidonium majus L. (Papaveraceae), against human leukemic and lung carcinoma cells", Phytomedicine, 23(3), pp.253~266 (2016), Elsevier BV[DOI]
10. Annie Panzer, "The effects of chelidonine on tubulin polymerisation, cell cycle progression and selected signal transmission pathways", European Journal of Cell Biology, 80(1), pp.111~118 (2001), Elsevier BV[DOI]
11. M COLOMBO, "PHARMACOLOGICAL ACTIVITIES OFCHELIDONIUM MAJUSL. (PAPAVERACEAE)", Pharmacological Research, 33(2), pp.127~134 (1996), Elsevier BV[DOI]
12. Gilca M, "Chelidonium majus--an integrative review : traditional knowledge versus modern findings", Forsch. Komplementmed, 17, pp.241~248 (2010)
13. Kokoska L, "Screening of some Siberian medicinal plants for antimicrobial activity", J. Ethnopharmacol, 82, pp.51~53 (2002)
14. Lee YC, "Suppressive effects of Chelidonium majus methanol extract in knee joint, regional lymph nodes, and spleen on collagen-induced arthritis in mice", J. Ethnopharmacol, 112, pp.40~48 (2007)
15. Noureini SK, "Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidonine", World J. Gastroenterol, 15, pp.3603~3610 (2009)
16. Lu JJ, "Alkaloids isolated from natural herbs as the anticancer agents", Evid. Based Complement. Alternat. Med, 2012, pp.485042~ (2012)
17. Kim O, "Chelidonine suppresses migration and invasion of MDA-MB-231 cells by inhibiting formation of the integrin-linked kinase", PINCH, Mol. Med. Rep, pp.2015, 12[DOI]
18. Noureini SK, "Multiple mechanisms of cell death induced by chelidonine in MCF-7 breast cancer cell line", Chem. Biol. Interact, 223, pp.141~149 (2014)
19. Lee KS, "Orostachys japonicus induce p53-dependent cell cycle arrest through the MAPK signaling pathway in OVCAR-3 human ovarian cancer cells", Food Sci. Nutr, 6, pp.2395~2401 (2018)
20. Noureini SK, "Selectivity of major isoquinoline alkaloids from Chelidonium majus towards telomeric G-quadruplex : A study using a transition-FRET(t-FRET)assay", Biochim. Biophys. Acta Gen. Subj, 1861, pp.2020~2030 (2017)
21. Zhang LQ, "Aloesin suppresses cell growth and metastasis in ovarian cancer SKOV3cells through the inhibition of the MAPK signaling pathway", Anal. Cell Pathol. (Amst), 2017, pp.8158254~ (2017)
22. Momenimovahed Z, "Ovarian cancer in the world : epidemiology and risk factors", Int. J. Womens Health, 11, pp.287~299 (2019)
23. Cho KR, "Ovarian cancer update : lessons from morphology, molecules, and mice", Arch. Pathol. Lab Med, 133, pp.1775~1781 (2009)
24. Karges DE, "Current concepts for treatment of the painful flatfoot in the elderly", Mo. Med, 102, pp.236~239 (2005)
25. Salzberg M, "Current concepts of treatment strategies in advanced or recurrent ovarian cancer", Oncology, 68, pp.293~298 (2005)
26. Jiang X, "Potential dual role of activating transcription factor 3 in colorectal cancer", Anticancer Res, 36, pp.509~516 (2016)
27. Guosheng Liang, "ATF3 Gene", Journal of Biological Chemistry, 271(3), pp.1695~1701 (1996), Elsevier BV[DOI]
28. Tsonwin Hai, "The molecular biology and nomenclature of the activating transcription factor", cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis, 2001, pp.273(1), 1~11[DOI]
29. Thompson MR, "ATF3 transcription factor and its emerging roles in immunity and cancer", J. Mol. Med(Berl), 87, pp.1053~1060 (2009)
30. Wang Z, "Emerging roles of ATF3 in the suppression of prostate cancer", Mol. Cell. Oncol, 3, pp.e1010948~ (2016)
31. Yin X, "A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development", Oncogene, 27, pp.2118~2127 (2008)
32. Bassi C, "The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair", Cell Death Differ, 23, pp.1198~1208 (2016)
33. Jang SM, "KAT5-mediated SOX4 acetylation orchestrates chromatin remodeling during myoblast differentiation", Cell Death Dis, 6, pp.e1857~ (2015)
34. Litvinov IV, "Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma", Oncoimmunology, 3, pp.e970025~ (2014)
35. Mattera L, "The p400", Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways, 2009, pp.28, 1506~1517
36. Pandey AK, "TIP60-miR-22 axis as a prognostic marker of breast cancer progression", Oncotarget, 6, pp.41290~41306 (2015)
37. Judes G, "A bivalent role of TIP60 histone acetyl transferase in human cancer", Epigenomics, 7, pp.1351~1363 (2015)
38. Huang H, "Dynamic FoxO transcription factors", J. Cell Sci, 120, pp.2479~2487 (2007)
39. Maiese K, "The"O"class : crafting clinical care with FoxO transcription factors", Adv. Exp. Med. Biol, 665, pp.242~260 (2009)
40. Guo S, "Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2", neu, Akt signaling pathway, pp.Mol. Cell. Biol, 2004[DOI]
41. Fernandez de Mattos S, "FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells", Mol. Cancer Ther, 7, pp.3237~3246 (2008)
42. Shukla S, "Apigenin inhibits prostate cancer progression in TRAMP mice via targeting PI3K", Akt, Carcinogenesis, pp.2014, 35[DOI]
43. Yu DS, "Expression of p-FOXO3", FOXO3 in bladder cancer and its correlation with clinicopathology and tumor recurrence, 2017, pp.10, 11069~11074
44. Taylor S, "Evaluating the evidence for targeting FOXO3a in breast cancer : a systematic review", Cancer Cell Int, 15, pp.1~ (2015)
45. Jang HJ, "Nectandrin B-mediated activation of the AMPK pathway prevents cellular senescence in human diploid fibroblasts by reducing intracellular ROS levels", Aging(Albany NY), 11, pp.3731~3749 (2019)
46. Park S, "BTNET : boosted tree based gene regulatory network inference algorithm using time-course measurement data", BMC Syst. Biol, 12, pp.20~ (2018)
47. Wilson AP, "Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary", J. Natl. Cancer Inst, 72, pp.513~521 (1984)
48. Mikolajczak PL, "Evaluation of antiinflammatory and analgesic activities of extracts from herb of Chelidonium majus L", Cent Eur. J. Immunol, 40, pp.400~410 (2015)
49. Isolani ME, "The in vivo effect of chelidonine on the stem cell system of planarians", Eur. J. Pharmacol, 686, pp.1~7 (2012)
50. Xie JJ, "ATF3 functions as a novel tumor suppressor with prognostic significance in esophageal squamous cell carcinoma", Oncotarget, 5, pp.8569~8582 (2014)
51. Huang X, "KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3", J. Biol. Chem, 283, pp.29795~29801 (2008)
52. Zhang X, "Akt, FoxO and regulation of apoptosis", Biochim. Biophys. Acta, 1813, pp.1978~1986 (2011)
53. Li Z, "Forkhead transcription factor FOXO3a protein activates nuclear factor kappaB through B-cell lymphoma", leukemia 10(BCL10)protein and promotes tumor cell survival in serum deprivation, 2012, pp.287, 17737~17745
54. Gong C, "Nuclear localization marker of FOXO3a : Can it be used to predict doxorubicin response?", Front. Oncol, 3, pp.149~ (2013)
55. Das TP, "Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer", Cell Death Dis, 7, pp.e2111~ (2016)
56. Sunters A, "Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt", Cancer Res, 66, pp.212~220 (2006)
57. Wilk A, "Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro", Cell Cycle, 11, pp.2660~2671 (2012)
58. Bowman KR, "Narrowing the field : cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer", J. Ovarian Res, 12, pp.38~ (2019)
59. Tang Y, "Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis", Mol. Cell, 24, pp.827~839 (2006)
60. Imamura Y, "Comparison of 2D-and 3D-culture models as drug-testing platforms in breast cancer", Oncol. Rep, 33, pp.1837~1843 (2015)
61. Nowacka M, "Drug resistance evaluation in novel 3D in vitro model", Biomed. Pharmacother, 138, pp.111536~ (2021)

관련 논문AI추천